Literature DB >> 2554710

Effects of calcium antagonists on lipids and atherosclerosis.

F Bernini1, A L Catapano, A Corsini, R Fumagalli, R Paolétti.   

Abstract

The arterial accumulation of cholesterol and calcium is a hallmark of atherosclerosis. Calcium antagonists (CAs) lessen the severity of experimentally induced atherosclerosis in cholesterol-fed animals. The reduction of aortic cholesterol is one of the most striking findings. This effect is achieved without a reduction of plasma lipid or blood pressure, and is probably related to an interference of CAs with lipid metabolism in the arterial wall. To what extent these properties of CAs are due to their ability to block calcium channels still remains to be addressed. This report briefly discusses the available in vivo and in vitro evidence for the antiatherosclerotic properties of CAs, and outlines the possible mechanisms by which these compounds affect cellular lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554710     DOI: 10.1016/0002-9149(89)90970-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  A comparative study on the effects of Gemfibrozil, Diltiazem and Isosorbide dinitrate on lipid profile in patients of ischemic heart disease in India.

Authors:  H O Sharma; S K Sharma
Journal:  Indian J Clin Biochem       Date:  1997-12

3.  Amlodipine induces a flow and pressure-independent vasoactive effect on the brachial artery in hypertension.

Authors:  J L Megnien; J Levenson; M Del-Pino; A Simon
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

4.  Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits.

Authors:  M R Soma; E Donetti; R Seregni; L Barberi; R Fumagalli; R Paoletti; A L Catapano
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 5.  Lipophilic calcium antagonists in antiatherosclerotic therapy.

Authors:  S Bellosta; F Bernini
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.967

Review 6.  Antioxidants and coronary artery disease.

Authors:  A L Catapano; E Tragni
Journal:  Curr Atheroscler Rep       Date:  1999-11       Impact factor: 5.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.